ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
2,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
3,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
3,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
4,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
5,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5,2,Haemorrhage subcutaneous,Skin haemorrhages,Skin vascular abnormalities,Skin,N
5,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
5,4,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
6,1,Inflammatory myofibroblastic tumour,Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas),Soft tissue neoplasms malignant and unspecified,Neopl,Y
6,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
7,1,Chest wall mass,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
7,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
7,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
8,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
8,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
8,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
8,5,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
9,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
10,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
10,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
11,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
12,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
13,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
13,2,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
14,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
15,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
15,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
16,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
17,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
18,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
19,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
20,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
20,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
20,3,Metastases to adrenals,Metastases to specified sites,Metastases,Neopl,N
20,4,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
20,5,Metastases to muscle,Metastases to specified sites,Metastases,Neopl,N
20,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
21,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
21,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
22,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
22,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
22,3,Vasogenic cerebral oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
23,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
24,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
25,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
26,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
27,1,Paralysis recurrent laryngeal nerve,Vagus nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
28,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
28,2,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
28,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
28,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
28,5,Paronychia,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
28,6,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
29,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
30,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
30,2,Musculoskeletal disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
31,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
31,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
31,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
31,4,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
32,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
32,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
32,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
33,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
34,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
35,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
35,2,Oxygen saturation abnormal,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
35,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
36,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
36,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
36,3,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
37,1,Amylase increased,Digestive enzymes,Gastrointestinal investigations,Inv,N
37,2,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
37,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
38,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
38,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
38,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
38,4,Lung adenocarcinoma,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
38,5,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
39,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
40,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
40,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
40,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
40,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
40,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
41,1,Acute interstitial pneumonitis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
42,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
43,1,Pulmonary alveolar haemorrhage,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
44,1,Blood creatine phosphokinase abnormal,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
44,2,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
44,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
45,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
46,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
47,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
47,2,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
48,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
49,1,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,N
